

**First Name: SHUANG**

**Last Name: LIU**

Laboratory of Systems Cancer Immunology  
Charité Universitätsmedizin  
Augustenburger Platz 1, 13353 Berlin, Germany  
Email: shuang.liu@outlook.de



## —Research Experience

*12/2019-06/2022 Laboratory of Tumor Molecular Genetics, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.*

Research focus: tumor molecular genetics and cancer immunology.

*09/2019-06/2022 Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.*

Research focus: radiotherapy and chemotherapy for colorectal cancer.

*06/2017-06/2019 Department of Epidemiology, School of Public Health, Nanchang University, Nanchang, China.*

Research focus: epidemiology and evidence-based medicine.

*12/2015-12/2018 Laboratory of Biochemistry and Molecular Biology, College of Basic Medical Science, Nanchang University, Nanchang, China.*

Research focus: association of sphingomyelin synthase with atherosclerosis, inflammation and oncogenesis.

## —Experimental Skills

Cytological techniques: Cell culture, Transfection, Wound healing assay, Transwell...

Animal Models: Subcutaneous transplant of tumor, Intra-splenic injection model...

Molecular Technology: qRT-PCR, PCR, Western blot, Immunofluorescence...

Statistical Software: R language, SPSS, Photoshop, Graphpad Prism, Image J...

## —Education Background

*09/2019-06/2022 Master of Medicine, Specialty: Oncology*

*Cancer Center, Sun Yat-sen University, Guangzhou, China.*

*09/2014-06/2019 Bachelor of Medicine, Specialty: Clinical Medicine*

*The School of Clinical Medicine, Nanchang University, Nanchang, China.*

## —Presentation

*05/2018 Oral presentation: the decipherment of RAPIDO trial (Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer: a randomised, open-label, phase 3 trial), The Tumor Radiotherapy Salon Meeting, Guangzhou, China.*

## —Publications

### Manuscripts

- 08/2022 **Liu S.#**, Yang S.#, Yu H.#, Luo H, Chen G, Gao Y, Sun R, Xiao W. A nomogram for predicting 10-year cancer specific survival in patients with pathological T3N0M0 rectal cancer. *Frontiers in medicine*, 2022;9:977652.
- 09/2021 **Liu S.#**, Jiang T.#, Xiao L.#, Yang S., Liu Q., Gao Y., Chen G., Xiao W. Total neoadjuvant therapy (TNT) versus standard neoadjuvant chemoradiotherapy for locally advanced rectal cancer: a systematic review and meta-analysis. *The Oncologist*, 26(9): e1555-e1566.
- 06/2021 Jiang T.#, **Liu S.#**, Wu X., Liu X., Li W., Yang S., Cai P., Xi S., Zeng Z., Gao Y., Gong G., Xiao W. Nomogram to predict distant metastasis probability for pathological complete response rectal cancer patients after neoadjuvant chemoradiotherapy. *Cancer Management and Research*, 13:4751-4761.
- 02/2019 **Liu S.#**, Hou H.#, Zhang P., Wu Y., He X., Li H., Yan N. Sphingomyelin synthase 1 regulates the epithelial-to-mesenchymal transition mediated by the TGF- $\beta$ /Smad pathway in MDA-MB-231 cells. *Molecular Medicine Reports*, 19 (2): 1159-1167.
- 09/2018 Lu F.#, **Liu S.#**, Hao Q., Liu L., Zhang J., Chen X., Hu W., Huang P. Association Between Complement Factor C2/C3/CFB/CFH Polymorphisms and Age-Related Macular Degeneration: A Meta-Analysis. *Genetic Testing and Molecular Biomarkers*, 22 (9): 526-540.

### Conference Abstracts

- 04/2022 **Liu S.**, Jiang T., Yan Y., Yu H., Guo Z., Gao Y., Li Y., Xiao W\*. Membrane spanning 4 domains A12 (MS4A12) c.C211T stop-gain single-nucleotide polymorphism (rs2298553) promotes metastasis in colorectal cancer via the Hippo pathway, Poster, AACR (American Association for Cancer Research), Louisiana, USA
- 01/2022 **Liu S.**, Xi S., Wu X., Cai P., Pan Z., Ding P., Chen G., Gao Y., Pan Z., Xiao W\*. A nomogram for predicting Cancer Specific Survival (CSS) in patients with pathological T3N0M0 (pT3N0M0) rectal cancer, Poster, ASCO-GI (American Society of Clinical Oncology-Gastrointestinal Cancers Symposium), California, USA
- 06/2021 Xiao W., Wu X., Cai P., Zhuang Y., Wang X., Bai S., Wang Q., Ye Y., Liu Q., Liu M., **Liu S.**, Zeng Z., Pan Z., Gao Y., Chen G. Total neoadjuvant treatment vErsus Standard chemoradiation to increase the Sphincter preservation rate for distal locally advanced rectal cancer (TESS). Poster, ASCO (American Society of Clinical Oncology), Online

### Chapters

- Liu S.**, Xiao W., Gao Y. *Neoadjuvant Therapy on Colorectal Cancer: Total Neoadjuvant Therapy*, People's Medical Publishing House, not published yet.
- Liu S.**, Xiao W., Gao Y. *Neoadjuvant Therapy on Colorectal Cancer: Neoadjuvant Therapy (Concurrent Chemoradiotherapy, Chemotherapy, Radiotherapy) Combined with Immunotherapy*, People's Medical Publishing House, not published yet.